With a $53.4 million market capitalization, NovaBay Pharmaceuticals (NBY) has given long-term shareholders a volatile year with a 52-week share range of $1.05-$1.76. For much of 2013, the company's common shares have traded around the $1.25 support/resistance range, just below the $1.40 resistance level it currently resides at. If there were no significant catalysts for 2H 2013, the company's shares could be in danger of returning closer to the mid-term $1.0 support range. However, significant events from its developing pipeline as well as potential upcoming updates of its single product offering may present investors with significant volatility in the coming weeks with much upside possible if events unfold favorably.
On June 11, NovaBay presented investors with a mid-year...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|